Publications by authors named "Matthew Ernst"

Claim this Profile
O
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kosuke Takemura, Audreylie Lemelin, Matthew S Ernst, J Connor Wells, Renee Maria Saliby

Eur Urol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Renée Maria Saliby, Matthew Scott Ernst, D Scott Ernst

Oncologist· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology.
Anish Tejura, Ricardo Fernandes, Stacey Hubay, Matthew Scott Ernst, Mario Valdes

Curr Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kosuke Takemura, Matthew S Ernst, Vishal Navani, J Connor Wells, Ziad Bakouny, D Scott Ernst

Eur Urol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Models in Metastatic Renal Cell Carcinoma.
Audreylie Lemelin, Kosuke Takemura, Daniel Y C Heng, Matthew S Ernst

Hematol Oncol Clin North Am· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
Matthew S Ernst, Vishal Navani, J Connor Wells, Frede Donskov, Naveen Basappa, D Scott Ernst

Eur Urol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Binghao Zhao, Hao Xing, and Wenbin Ma's Letter to the Editor re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116.
Matthew S Ernst, Daniel Y C Heng

Eur Urol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma" [Eur Urol 2023].
Matthew S Ernst, Vishal Navani, J Connor Wells, Frede Donskov, Naveen Basappa, D Scott Ernst

Eur Urol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
Kosuke Takemura, Vishal Navani, Matthew S Ernst, J Connor Wells, Luis Meza

J Urol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma.
Vishal Navani, Matthew Ernst, J Connor Wells, Takeshi Yuasa, Kosuke Takemura, D Scott Ernst

JAMA Netw Open· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.
Matthew S Ernst, John T Lysack, Martin D Hyrcza, Shamir P Chandarana, Desiree Hao

Curr Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine-like receptor 1 regulates skeletal muscle cell myogenesis.
Mark E Issa, Shanmugam Muruganandan, Matthew C Ernst, Sebastian D Parlee, Brian A Zabel

Am J Physiol Cell Physiol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A procedure for creating a frailty index based on deficit accumulation in aging mice.
Randi J Parks, Elias Fares, Jennifer K Macdonald, Matthew C Ernst, Christopher J Sinal

J Gerontol A Biol Sci Med Sci· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance.
Matthew C Ernst, Ian D Haidl, Luis A Zúñiga, Helen J Dranse, Jillian L Rourke

Endocrinology· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemerin, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis.
Shanmugam Muruganandan, Sebastian D Parlee, Jillian L Rourke, Matthew C Ernst, Kerry B Goralski

J Biol Chem· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice.
Matthew C Ernst, Christopher J Sinal, P Timothy Pollak

Pharmacol Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemerin: at the crossroads of inflammation and obesity.
Matthew C Ernst, Christopher J Sinal

Trends Endocrinol Metab· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}.
Sebastian D Parlee, Matthew C Ernst, Shanmugam Muruganandan, Christopher J Sinal, Kerry B Goralski

Endocrinology· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes.
Matthew C Ernst, Mark Issa, Kerry B Goralski, Christopher J Sinal

Endocrinology· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis